Redefining the therapeutic objective in psoriatic patients candidates for biological therapy


Por: Carretero, G, Puig, L, Carrascosa, J, Ferrandiz, L, Ruiz-Villaverde, R, de la Cueva, P, Belinchon I, Vilarrasa, E, del Rio, R, Sanchez-Carazo, J, Lopez-Ferrer, A, Peral, F, Armesto, S, Eiris, N, Mitxelena, J, Vilar-Alejo, J, Martin, M and Soria, C

Publicada: 1 ene 2018
Categoría: Dermatology

Resumen:
The advances in psoriasis management currently allow achieving a good control of the disease. In particular, with the latest developed molecules, available evidence suggests that it is possible to pose an ambitious therapeutic goal, such as a Dermatology Life Quality Index 0/1, a Physician Global Assessment 0/1, or a Psoriasis Area and Severity Index 90/100 response. However, patients often fail to achieve the complete clearance of their cutaneous lesions or the improvement of disease factors that impair their quality of life. To optimize the treatment of psoriasis, it is not enough to define precisely the therapeutic objective, but also to adapt the therapeutic strategy to make the necessary modifications in case of not achieving it at the time point (at the end of the induction phase, or every 3-6months) to be agreed with the patient (the so-called treat-to-target approach). In the present report, based on the Delphi methodology, 11 dermatologists from the Spanish Psoriasis Group addressed key issues that could be involved in the achievement and maintenance of the therapeutic goals of patients with moderate to severe psoriasis. The document provides 27 consensus statements intended to support clinical decision-making by healthcare professionals for patients who might be candidates to receive biologic therapy.

Filiaciones:
Carretero, G:
 Hosp Univ Gran Canaria Doctor Negrin, Las Palmas Gran Canaria, Spain

Puig, L:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain

Carrascosa, J:
 Univ Autonoma Barcelona, Hosp Univ Germans Trias & Pujol, Badalona, Spain

Ferrandiz, L:
 Hosp Univ Virgen Macarena, Seville, Spain

Ruiz-Villaverde, R:
 Complejo Hosp Granada, Granada, Spain

de la Cueva, P:
 Hosp Univ Infanta Leonor, Madrid, Spain

Belinchon I:
 Hosp Gen Univ Alicante ISABIAL, Alicante, Spain

Vilarrasa, E:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain

del Rio, R:
 Fundacio Hosp Esperit St, Santa Coloma De Gramenet, Spain

Sanchez-Carazo, J:
 Consorcio Hosp Gen Univ Valencia, Valencia, Spain

Lopez-Ferrer, A:
 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Barcelona, Spain

Peral, F:
 Hosp Univ Infanta Cristina Badajoz, Badajoz, Spain

Armesto, S:
 Hosp Univ Marques de Valdecilla, Santander, Spain

Eiris, N:
 Complejo Asistencial Univ Leon, Leon, Spain

Mitxelena, J:
 Complejo Hosp Navarra, Navarra, Spain

Vilar-Alejo, J:
 Hosp Univ Gran Canaria Doctor Negrin, Las Palmas Gran Canaria, Spain

Martin, M:
 Hosp Clin Univ Lozano Blesa, Zaragoza, Spain

Soria, C:
 Hosp Gen Univ Reina Sofia, Murcia, Spain
ISSN: 09546634





JOURNAL OF DERMATOLOGICAL TREATMENT
Editorial
TAYLOR & FRANCIS LTD, 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 29 Número: 4
Páginas: 334-346
WOS Id: 000433547000004
ID de PubMed: 29099667

MÉTRICAS